Study Links COVID Vaccines to Rare Disorders 

Since the pandemic began, over 13.5 billion COVID-19 vaccine doses have been administered globally, a crucial step in combating the virus. Approximately 71% of the world’s population has received at least one vaccine dose.

However, concerns have emerged from a recent study published in a peer-reviewed journal, indicating a potential link between vaccines from leading manufacturers like Pfizer, Moderna, and AstraZeneca and rare cases of heart, brain, and blood disorders.

The Global Vaccine Data Network, associated with the World Health Organization (WHO), conducted an extensive study, the largest of its kind, on the COVID-19 vaccine. This research compared the expected versus actual occurrences of 13 medical conditions deemed as “adverse events of special interest” among 99 million vaccinated individuals in eight countries. Key findings include:

• Instances of myocarditis (heart inflammation) were notably rare but identified in those who received Pfizer-BioNTech’s and Moderna’s mRNA vaccines, particularly after the second Moderna dose, showing a 6.1 times increase in expected rates.
• A third dose of AstraZeneca’s vaccine was associated with a 6.9 times higher risk of Pericarditis (another heart condition), with Moderna’s vaccine showing 1.7 times and 2.6 times increased risks after the first and fourth doses, respectively.
• The risk of Guillain-Barre syndrome, a rare autoimmune disorder, was 2.5 times higher, and blood clots were 3.2 times more likely among AstraZeneca vaccine recipients.
• Increased risks of the neurological disorder acute disseminated encephalomyelitis were observed, 3.8 times higher after the Moderna vaccine and 2.2 times after AstraZeneca’s vaccine.